Ibrahim Altamawy | Medical Affairs & Compliance Regional Head (MENA)
SAJA Pharmaceuticals

Ibrahim Altamawy Regional Medical Affairs & Compliance Head | Medical Strategy Leader | Pharmacovigilance Expert With over 20 years of experience in Medical Affairs, Compliance, and Pharmacovigilance, Ibrahim Altamawy is a strategic leader specializing in accelerating patient access and enhancing clinical practices across the MENA region. His expertise spans Gastroenterology, Primary Care, Cardiovascular & Diabetes, Urology, Pain Care, and Anti-Infectives, with a proven track record of launching innovative medical programs, optimizing regulatory compliance, and driving cross-functional medical strategies. As Regional Medical Affairs & Compliance Head at SAJA Pharmaceuticals, Ibrahim spearheads initiatives that bridge medical science with business objectives, ensuring regulatory adherence while maximizing patient impact. Previously, at Novartis and AbbVie, he led franchise medical strategy, market access collaborations, clinical research oversight, and patient support programs, pioneering projects that transformed healthcare accessibility. A former QPPV, Ibrahim has played a pivotal role in pharmacovigilance and medical quality management across Egypt, Saudi Arabia, and the Gulf. He successfully led compliance initiatives, achieving green global audit results and contributing to the implementation of Arab GVP guidelines. His leadership in medical governance, digital transformation, and talent development has positioned him as a key influencer in the industry. Ibrahim holds a Master’s in Clinical Nutrition, an MBA from RB College (UK), and a Postgraduate Diploma in Biochemistry & Hematology. He has also completed extensive training in clinical research, pharmacoeconomics, and strategic medical leadership across Europe and the Middle East. Recognized for driving innovation and excellence, Ibrahim has received multiple Presidential and Regional Medical Awards, including the Vice-President Award for Medical Operations in MEA and the Global Excellence Award for Neonatal Care. He remains committed to shaping the future of medical affairs, ensuring better patient outcomes and regulatory excellence in the evolving pharmaceutical landscape